Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Retatrutide reduced bodyweight by up to 18.8% in adults with obesity and type 2 diabetes over 80 weeks, outperforming placebo in a phase 3 trial.

• Why it matters: Obesity and type 2 diabetes are major health issues with limited effective long-term treatments, highlighting the need for new therapies that can improve weight and glycemic control safely.
• What they did: A double-blind, randomized, placebo-controlled trial enrolled 1152 adults with obesity and type 2 diabetes, administering weekly injections of retatrutide at different doses and measuring weight change and safety outcomes.
• The result: Retatrutide led to significant weight loss and improved glycemic control, with manageable side effects, suggesting it could be a promising treatment option for obesity and diabetes management.